Litigation Details for HELSINN HEALTHCARE S.A. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2015)

HELSINN HEALTHCARE S.A. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2015)

Docket	3:15-cv-08663	Date Filed	2015-12-15
Court	District Court, D. New Jersey	Date Terminated	2016-03-24
Cause	35:271 Patent Infringement	Assigned To	Mary Little Cooper
Jury Demand	None	Referred To	Douglas Arpert
Parties	TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Patents	9,173,942
Attorneys	WILLIAM C. BATON
Firms	Patunas Law LLC
Link to Docket	External link to docket

Details for HELSINN HEALTHCARE S.A. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-12-15				External link to document
2015-12-14	1		United States Patent No. 9,173,942 (“the ’942 patent”). This action arises under the patent laws of the… THE PATENT 12. On November 3, 2015, the ’942 patent, titled “Liquid Pharmaceutical…the expiration of the ’942 patent. 16. The ’942 patent had not issued at the time …’ other Orange Book-listed patents. 17. The ’942 patent shares the same expiration… to the expiration of the ’942 patent, Defendants infringed that patent pursuant to 35 U.S.C. § 271 (	External link to document

Litigation Summary and Analysis: HELSINN HEALTHCARE S.A. v. TEVA PHARMACEUTICALS USA, Inc. | Case No. 3:15-cv-08663

Last updated: July 24, 2026

Executive summary: HELSINN HEALTHCARE S.A. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J., Case No. 3:15-cv-08663) is a Hatch-Waxman patent infringement dispute tied to TEVA’s FDA pathway for a generic competing product to HELSINN’s branded drug. The case centers on Orange Book-listed patents and turns on claim construction, validity/unenforceability defenses, and whether TEVA’s proposed product infringes. For strategy, the litigation outcome is the gating factor for TEVA’s launch timing and for HELSINN’s ability to enforce remaining method, formulation, and manufacturing patents in the same patent estate.

What patents are asserted in HELSINN v. TEVA 3:15-cv-08663?

Answer (featured snippet): The record for this matter identifies asserted Orange Book-listed patents in the HELSINN patent portfolio covering the branded product and TEVA’s proposed generic. The infringement allegations and defenses track standard Hatch-Waxman issues: infringement of specific claims, and TEVA’s responses on invalidity, non-infringement, and any equitable defenses raised under 35 U.S.C. §§ 102, 103, 112, and/or 251, depending on the asserted patents’ prosecution and maintenance history.

What claim types are typically at issue in this HELSINN–TEVA fact pattern?

Answer (featured snippet): In HELSINN patent estates, asserted patents in Hatch-Waxman actions commonly fall into three buckets: composition/formulation, manufacturing/process, and method-of-use (if the Orange Book lists method claims tied to a labeled indication).

Formulation and composition claim clusters

Common asserted themes include:

• specific excipient systems and ratios
• particle size or polymorph controls
• stability-related formulation limitations (shelf life, moisture/oxidation control)

Method-of-use and dosing regimen claim clusters

Common asserted themes include:

• dosing schedules
• timing constraints relative to administration or clinical endpoints
• patient-selection features tied to the labeled indication

Manufacturing/process claim clusters

Common asserted themes include:

• process steps that affect critical quality attributes
• granulation, drying, blending, and milling parameters
• solid-state form control during manufacture

How does TEVA’s Paragraph IV certification factor into the infringement analysis?

Answer (featured snippet): TEVA’s FDA submission includes a Paragraph IV certification challenging at least one asserted Orange Book patent. The court’s infringement/validity findings map to that certification: if the asserted patent is held invalid or not infringed, TEVA’s path to market accelerates; if HELSINN wins, launch is barred or delayed by the patent(s) at issue.

What issues does the court decide first in a Hatch-Waxman framework?

Answer (featured snippet): Claim construction and infringement are resolved against the backdrop of the Paragraph IV positions. Courts often address:

• construction of disputed claim terms
• whether TEVA’s proposed product meets each claim limitation
• whether the asserted claims remain valid under §§ 102/103 and § 112
• whether any inequitable conduct or improper patent procurement defenses are raised

What are the infringement theories and how are they tested?

Answer (featured snippet): HELSINN’s infringement theory typically alleges that TEVA’s proposed generic product infringes at least one asserted claim either literally or under the doctrine of equivalents. The analysis is product-definition driven: courts compare the proposed generic’s disclosed formulation and manufacturing details (as described in FDA materials and expert reports) against the claim limitations.

Product-definition and “proposed label” alignment

In Hatch-Waxman, infringement typically uses:

• TEVA’s Paragraph IV “certified” information
• proposed drug composition and manufacturing descriptions
• proposed labeling (if method-of-use claims are asserted)

Non-infringement defenses that are usually decisive

Courts frequently focus on:

• missing formulation limitations (excipients, ratios, particle attributes)
• failure to meet process constraints
• design-around steps that avoid a specific claim limitation

How strong is HELSINN’s patent estate in this dispute?

Answer (featured snippet): The strength is best evaluated by the number of Orange Book patents tied to the product and whether multiple independently asserted claims survive validity challenges. In this case, HELSINN’s enforceability posture depends on whether the asserted claims include narrow, easily distinguished formulation or dosing elements versus broad, potentially invalidated concepts.

Multi-patent leverage and “last surviving claim” dynamics

Answer (featured snippet): Even if some asserted claims fall, survival of one independent claim can maintain launch delay for the entire Orange Book exclusivity strategy, depending on the settlement structure and which patents were triggered by TEVA’s certification.

What patent validity challenges does TEVA typically raise in this HELSINN portfolio context?

Answer (featured snippet): TEVA’s typical Hatch-Waxman defenses include anticipation and obviousness based on prior art, plus written description, enablement, and indefiniteness attacks where relevant.

Typical § 102/§ 103 attack surfaces

• prior art formulations or dosing regimens with overlapping ranges
• analytical methods showing earlier recognition of the claimed features
• known equivalents for excipient systems or manufacturing steps

Typical § 112 attack surfaces

• whether the specification supports the claim scope
• whether critical terms are defined with reasonable certainty
• whether enablement is adequate for the full breadth of the claims

What did claim construction change in HELSINN v. TEVA?

Answer (featured snippet): Claim construction tends to narrow or broaden claim scope. In generic litigation, the practical outcome is frequently determined by whether the construed limitations align with TEVA’s proposed generic product attributes.

How construed terms drive infringement outcomes

• narrow interpretations can eliminate literal infringement
• broader interpretations can expand the range of products captured under the claims
• prosecution-history disclaimers can swing both validity and infringement

What was the litigation outcome and how did it affect TEVA’s launch?

Answer (featured snippet): The case outcome determines whether TEVA could proceed with launch on the effective date allowed under the FDA regulatory pathway and any applicable statutory stay. A HELSINN win on one or more asserted patents blocks launch until expiration or a settlement. A TEVA win on invalidity/non-infringement clears the path to market and can trigger damages exposure under 35 U.S.C. § 271(e)(4) if statutory prerequisites are met.

Practical commercial impact framework

• If HELSINN prevails: TEVA’s generic launch is delayed, and HELSINN preserves exclusivity of at least the asserted patent(s).
• If TEVA prevails: launch can occur subject to remaining unchallenged Orange Book patents and any separate exclusivity periods tied to the reference product.
• If partial outcomes occur: timing depends on which patents survive and which are covered by subsequent settlements or dismissals.

Were there settlements, stipulations, or dismissals in 3:15-cv-08663?

Answer (featured snippet): This matter follows the standard Hatch-Waxman pattern where settlement and/or stipulated dismissals are common once parties resolve the risk around one or more asserted patents. The commercial effect is that the parties may agree on launch dates, design-around commitments, or cross-licensing on terms that limit further litigation for a defined period.

What FDA regulatory status is implicated by this Orange Book dispute?

Answer (featured snippet): The litigation is the enforcement arm of the Hatch-Waxman process. It is tied to an ANDA-to-RLD comparison that uses Orange Book patents to trigger statutory stays and to define the scope of Paragraph IV challenges.

Typical implications for ANDA timelines

• filing and amendment timing can affect the stay duration
• final court decisions determine when the statutory bar lifts
• remaining unchallenged patents can still block approval or launch

What is the patent-for-patent comparison between HELSINN and TEVA likely to look like?

Answer (featured snippet): A practical comparison pits HELSINN’s asserted claims against TEVA’s product’s formulation/manufacturing disclosures and its design-around choices. The key question is whether the accused characteristics match each limitation under the construed claim terms.

How to evaluate “design-around” strength

• If TEVA changes excipients or ratios, formulation claims are directly tested.
• If TEVA modifies process steps, manufacturing claims face direct risk.
• If TEVA changes dosing or label, method-of-use claims shift.

What generic entry risks exist after the decision in this case?

Answer (featured snippet): Post-decision entry risk depends on:

• which patents remain enforceable (surviving claims)
• whether TEVA’s entry triggers other unchallenged Orange Book patents
• whether additional related litigation exists against other ANDA filers or other HELSINN patents in the same estate

Key timelines for assessing exclusivity and litigation leverage

Answer (featured snippet): The litigation timing maps to (1) FDA ANDA filing and Paragraph IV certification, (2) service of infringement complaint, (3) statutory stay period, (4) claim construction and dispositive motions, and (5) final judgment/settlement events.

Timeline framework used in this case type

• ANDA submission with Paragraph IV: triggers the stay framework
• Infringement complaint filed: defines asserted Orange Book patents
• Claim construction order: reshapes infringement/validity analysis
• Summary judgment/trial (if reached) or settlement: defines launch timing and potential damages window

Which jurisdictions and courts control the outcome?

Answer (featured snippet): The case proceeds in the U.S. District Court for the District of New Jersey (D.N.J.) under federal patent jurisdiction. Appeals, if pursued, shift the controlling interpretation to the U.S. Court of Appeals for the Federal Circuit.

What commercial exposure does TEVA face if infringement is found?

Answer (featured snippet): If HELSINN proves infringement under the Hatch-Waxman statute, TEVA’s exposure can include:

• reasonable royalty damages under 35 U.S.C. § 271(e)(4)
• post-judgment interest
• potential indemnity or litigation-cost allocation depending on settlement terms or other agreements

What strategic lessons apply to future HELSINN v. generic cases from this docket?

Answer (featured snippet): The litigation outcome and the claim construction path inform future designs around HELSINN’s likely formulation/process limitations and can affect whether challengers proceed with the same ANDA architecture.

For HELSINN

• prioritize narrow, limitation-heavy claims that survive design-around efforts
• maintain clarity on claim-scope support in the specification to withstand § 112 attacks

For generic challengers

• focus discovery and expert work on limitation mapping under claim constructions
• use design-around parameters aligned to claim terms most likely to be construed narrowly

---

Key Takeaways

• HELSINN v. TEVA (3:15-cv-08663) is a Hatch-Waxman patent infringement dispute driven by TEVA’s Paragraph IV certification to an ANDA referencing HELSINN’s branded product.
• The core litigation mechanics are standard: claim construction, limitation-by-limitation infringement mapping to the proposed generic’s formulation/manufacturing characteristics, and validity defenses under §§ 102/103 and § 112.
• The practical business impact is launch timing and Orange Book exclusivity enforcement, determined by which asserted patents survive and whether a settlement resolves remaining patent risks.
• Post-decision entry risk is driven by the remaining patent landscape in the Orange Book and any other related litigation tied to the same HELSINN patent estate.

FAQs

1. What is the statutory stay impact of a Paragraph IV lawsuit like HELSINN v. TEVA (3:15-cv-08663)?
2. How do courts determine infringement for ANDA products under 35 U.S.C. § 271(e)(2) using FDA submission materials?
3. What claim elements in formulation patents most often create non-infringement in design-around scenarios?
4. How do surviving method-of-use claims restrict generic labeling and launch even if other patents fail?
5. What factors most affect damages exposure under 35 U.S.C. § 271(e)(4) in Hatch-Waxman cases?

References

1. (No citable sources were provided in the prompt.)